Last reviewed · How we verify
NCT06978829
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Phase 2 trial testing TP + Cetuximab + Tislelizumab in LA HNSCC in 42 participants. Currently enrolling.
31 March 2027
Quick facts
| Lead sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 1 March 2025 |
| Primary completion | 31 March 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- TP + Cetuximab + Tislelizumab — full drug profile →
Conditions studied
- LA HNSCC — all drugs for LA HNSCC →
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Who can join
18 and older, any sex, with LA HNSCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06978829
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials
Trials by the same sponsor.
- NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
- NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
- NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
- NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
- NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06978829 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978829.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing